Freeline Therapeutics (FRLN) to Release Quarterly Earnings on Wednesday

Freeline Therapeutics (NASDAQ:FRLN) will be posting its quarterly earnings results on Wednesday, November 22nd.

Freeline Therapeutics Trading Up 14.7 %

Shares of NASDAQ:FRLN opened at $5.76 on Tuesday. Freeline Therapeutics has a twelve month low of $2.11 and a twelve month high of $10.20. The company’s 50 day moving average is $4.43 and its 200 day moving average is $3.77. The company has a market cap of $25.00 million, a PE ratio of -0.69 and a beta of 0.39.

Hedge Funds Weigh In On Freeline Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of FRLN. Acadian Asset Management LLC purchased a new position in Freeline Therapeutics during the first quarter worth approximately $30,000. Northern Trust Corp acquired a new position in shares of Freeline Therapeutics during the 2nd quarter worth about $40,000. Federated Hermes Inc. raised its holdings in shares of Freeline Therapeutics by 50.0% during the first quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock valued at $67,000 after acquiring an additional 20,000 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Freeline Therapeutics by 17.4% in the first quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock valued at $105,000 after acquiring an additional 34,210 shares in the last quarter. Finally, UBS Group AG acquired a new stake in shares of Freeline Therapeutics in the first quarter worth approximately $565,000. Hedge funds and other institutional investors own 46.26% of the company’s stock.

Analysts Set New Price Targets

FRLN has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Freeline Therapeutics in a report on Thursday, August 17th. Wedbush lowered shares of Freeline Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the company from $8.00 to $5.00 in a report on Wednesday, October 18th.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.